{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:49:00Z","timestamp":1762980540815,"version":"3.40.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.trsl.2018.05.009","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T03:45:48Z","timestamp":1528861548000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-7292","authenticated-orcid":false,"given":"Thomas","family":"Gremmel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.05.009_bib0001","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","article-title":"Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome","volume":"68","author":"Budde","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.trsl.2018.05.009_bib0003","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.trsl.2018.05.009_bib0004","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0005","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0006","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0007","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.trsl.2018.05.009_bib0009","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.12759","article-title":"Influence of platelet and white blood cell counts on major thrombosis\u2014analysis from a patient registry in essential thrombocythemia","volume":"97","author":"Buxhofer-Ausch","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ejh.12554","article-title":"Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide","volume":"96","author":"Schwarz","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13070","article-title":"Impact of white blood cells on thrombotic risk in patients with optimised platelet count in essential thrombocythemia","author":"Buxhofer-Ausch","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0012","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2011-02-337337","article-title":"Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia","volume":"118","author":"Maugeri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)","volume":"29","author":"Barosi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2018.05.009_bib0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.05.009_bib0016","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","article-title":"Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry","volume":"64","author":"Mayer","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2018.05.009_bib0017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1538-7836.2007.02498.x","article-title":"Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection","volume":"5","author":"Cattaneo","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2018.05.009_bib0018","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \"resistance\"","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2016.04.006","article-title":"Multiple electrode aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance","volume":"142","author":"Gillet","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.trsl.2018.05.009_bib0020","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","article-title":"Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia","volume":"129","author":"Dillinger","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.trsl.2018.05.009_bib0022","doi-asserted-by":"crossref","unstructured":"Perrier-Cornet A, Ianotto JC, Mingant F, Perrot M, Lippert E, Galinat H. Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. Platelets 2017:1\u20136.","DOI":"10.1080\/09537104.2017.1361018"},{"key":"10.1016\/j.trsl.2018.05.009_bib0023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0024","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jacc.2003.12.034","article-title":"Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment","volume":"43","author":"Chen","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2018.05.009_bib0026","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/09537104.2016.1240769","article-title":"Underlying mechanism and specific prevention of hemolysis-induced platelet activation","volume":"28","author":"Gremmel","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.trsl.2018.05.009_bib0027","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2018.05.009_bib0028","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0029","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0030","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1538-7836.2008.03184.x","article-title":"Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests","volume":"6","author":"Frelinger","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2018.05.009_bib0031","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2009.01.037","article-title":"Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin","volume":"143","author":"Lordkipanidze","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0032","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/MBC.0b013e3283655640","article-title":"Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study","volume":"24","author":"Jastrzebska","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.trsl.2018.05.009_bib0033","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2141.2001.03101.x","article-title":"Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis","volume":"115","author":"Joseph","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0034","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1538-7836.2007.02462.x","article-title":"Indices of platelet activation and the stability of coronary artery disease","volume":"5","author":"Linden","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trsl.2018.05.009_bib0035","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/1755-5922.12021","article-title":"Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel","volume":"31","author":"Gremmel","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.trsl.2018.05.009_bib0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjh.14202","article-title":"Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis","volume":"179","author":"Buxhofer-Ausch","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trsl.2018.05.009_bib0037","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11739-015-1186-8","article-title":"Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia","volume":"10","author":"Piccin","year":"2015","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.trsl.2018.05.009_bib0038","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11630740-000000000-00000","article-title":"Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications","volume":"51","author":"Floyd","year":"2012","journal-title":"Clin Pharmacokinet"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T07:08:10Z","timestamp":1571468890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418300926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":38,"alternative-id":["S1931524418300926"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.05.009","relation":{},"ISSN":["1931-5244"],"issn-type":[{"type":"print","value":"1931-5244"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}